• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

1.270 +0.010 (+0.79%)
Streaming Delayed Price Updated: 1:07 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 206,005
Open 1.330
Bid (Size) 1.240 (400)
Ask (Size) 1.270 (100)
Prev. Close 1.260
Today's Range 1.250 - 1.330
52wk Range 0.9631 - 34.75
Shares Outstanding 2,172,309
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
May 14, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Supply Chain
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
May 14, 2026
ATLANTA, GA - May 14, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer,... 
Via TheNewswire.com
Topics Supply Chain

Performance

YTD
-75.5%
-75.5%
1 Month
-5.2%
-5.2%
3 Month
-45.0%
-45.0%
6 Month
-89.2%
-89.2%
1 Year
-94.4%
-94.4%

More News

Read More
News headline image
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors
May 13, 2026
Via NewMediaWire
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors
May 13, 2026
Via TheNewswire.com
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
April 02, 2026
Via NewMediaWire
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
April 02, 2026
Via TheNewswire.com
GeoVax Provides Update on GEO-MVA Program
March 25, 2026
Via TheNewswire.com
Which stocks have an unusual volume on Friday? ↗
May 08, 2026
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session. ↗
May 07, 2026
Via Chartmill
News headline image
GeoVax Announces a Warrant Inducement Transaction
May 07, 2026
Via NewMediaWire
GeoVax Announces a Warrant Inducement Transaction
May 07, 2026
Via TheNewswire.com
News headline image
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
May 06, 2026
Via NewMediaWire
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
May 06, 2026
Via TheNewswire.com
News headline image
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities
April 29, 2026
Via NewMediaWire
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities
April 29, 2026
Via TheNewswire.com
News headline image
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies
April 27, 2026
Via NewMediaWire
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies
April 27, 2026
Via TheNewswire.com
News headline image
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
April 15, 2026
Via NewMediaWire
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
April 15, 2026
Via TheNewswire.com
News headline image
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
April 14, 2026
Via NewMediaWire
Topics Economy Supply Chain
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
April 14, 2026
Via TheNewswire.com
Topics Economy Supply Chain
News headline image
GeoVax Announces a Warrant Inducement Transaction
March 31, 2026
Via NewMediaWire
GeoVax Announces a Warrant Inducement Transaction
March 31, 2026
Via TheNewswire.com
News headline image
GeoVax Provides Update on GEO-MVA Program
March 25, 2026
Via NewMediaWire
News headline image
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients
March 12, 2026
Via NewMediaWire

Frequently Asked Questions

Is GeoVax Labs, Inc. - Common Stock publicly traded?
Yes, GeoVax Labs, Inc. - Common Stock is publicly traded.
What exchange does GeoVax Labs, Inc. - Common Stock trade on?
GeoVax Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for GeoVax Labs, Inc. - Common Stock?
The ticker symbol for GeoVax Labs, Inc. - Common Stock is GOVX on the Nasdaq Stock Market
What is the current price of GeoVax Labs, Inc. - Common Stock?
The current price of GeoVax Labs, Inc. - Common Stock is 1.270
When was GeoVax Labs, Inc. - Common Stock last traded?
The last trade of GeoVax Labs, Inc. - Common Stock was at 05/15/26 01:07 PM ET
What is the market capitalization of GeoVax Labs, Inc. - Common Stock?
The market capitalization of GeoVax Labs, Inc. - Common Stock is 2.76M
How many shares of GeoVax Labs, Inc. - Common Stock are outstanding?
GeoVax Labs, Inc. - Common Stock has 3M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap